SABCS Highlights

“If you want something you never had, you have to do something you’ve never done.” So, reputedly, said a Mr Thomas Jefferson, in a different age and in a different place, but the advice remains timeless. The quotation comes to our mind as, at the time of writing, we reflect at the end of the […]

Paediatric low-grade gliomas (pLGGs) most commonly develop in the cerebellum and can be resected safely, with minimal neurological complications and long-term cure achieved following surgery alone.1 However, a large proportion of pLGGs that develop in other parts of the brain remain unresectable and ultimately manifest as a chronic disease.2 The most common location at which unresectable pLGG […]

In recent years, our understanding of the complement system and its role in disease has increased dramatically. With the advent of complement 5 (C5) and C3 inhibitors, our ability to manipulate the complement system has improved the outcomes and quality of life for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic–uraemic syndrome.1–3 More recently, this understanding […]

Bladder cancer (BC) is the sixth most common cancer in the world, accounting for 81,180 estimated new cases and 17,100 deaths in 2022.1 BC is most frequently diagnosed among people aged 65–74 years.1 For patients with disease limited to the bladder, the depth of invasion of the primary tumour is the most important prognostic variable in […]

The optimal maintenance approach postautologous stem cell transplantation (ASCT) for patients with multiple myeloma is still an area of ongoing research. Lenalidomide has demonstrated clear superiority in clinical trials compared to placebo, and continuous post-transplant lenalidomide until progression is considered standard of care. All patients, however, do not derive equal benefit from single-agent lenalidomide, and […]

Welcome to the latest edition of touchREVIEWS in Oncology & Haematology, which features a wealth of topical and practical content for oncologists and haematologists, as well as being of interest to the wider medical community. We open with an editorial by Joseph Franz and Sagar Lonial, looking at the potential of the ATLAS trial (ClinicalTrials.gov Identifier: […]

Head and neck squamous cell carcinomas (HNSCCs) encompass a diverse group of tumours arising from the nasopharynx, oral cavity, oropharynx, hypopharynx and larynx. Tobacco and alcohol abuse are risk factors for the development of HNSCC, particularly oral cavity, hypopharyngeal and laryngeal cancers, whereas Epstein–Barr virus (EBV) and human papillomavirus (HPV) can mediate tumourigenesis in nasopharyngeal […]

Cancers of the oesophagus and oesophagogastric junction (OGJ), termed upper gastrointestinal (UGI) cancers, are lethal and constitute a significant public health problem. In 2020, 604,000 cases and 544,000 UGI cancer-related deaths were estimated worldwide.1 UGI cancers are the seventh most frequently diagnosed cancer and the sixth most common cause of cancer-related death.1 In the USA, there were […]

Acute myeloid leukaemia (AML) is a heterogeneous haematological malignancy characterized by the presence of ≥20% blasts in bone marrow or peripheral blood or the presence of defined genetic abnormalities.1 In 2020, there were an estimated 21,450 new patients with AML and 11,180 AML-related deaths in the USA.2 Most mutated myeloid stem cells proliferate due to genetic alterations, […]